Voloridge Investment Management’s AbCellera Biologics ABCL Stock Holding History

Voloridge Investment Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$560K	Sell	71,345 -539,078	-88%	-$2.64M	﹤0.01%	754
2026 Q1	$2.13M	Sell	610,423 -85,373	-12%	-$307K	0.01%	820
2025 Q4	$2.38M	Buy	695,796 +438,061	+170%	+$1.96M	0.01%	891
2025 Q3	$1.3M	Buy	+257,735	New	+$1.14M	﹤0.01%	1005
2024 Q2	–	Sell	-13,448	Closed	-$60.9K	–	1183
2024 Q1	$60.9K	Buy	+13,448	New	+$68.6K	﹤0.01%	1116
2023 Q3	–	Sell	-97,323	Closed	-$629K	–	1346
2023 Q2	$629K	Sell	97,323 -27,921	-22%	-$191K	﹤0.01%	1200
2023 Q1	$944K	Buy	+125,244	New	+$1.14M	﹤0.01%	1135
2022 Q3	–	Sell	-196,406	Closed	-$2.09M	–	1366
2022 Q2	$2.09M	Buy	196,406 +66,524	+51%	+$563K	0.01%	999
2022 Q1	$1.27M	Buy	+129,882	New	+$1.23M	0.01%	1073
2021 Q3	–	Sell	-174,428	Closed	-$3.84M	–	1610
2021 Q2	$3.84M	Buy	+174,428	New	+$4.81M	0.03%	737

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Voloridge Investment Management's ABCL Position: Q2 2026 in Review

Voloridge Investment Management reduced its AbCellera Biologics (ABCL) stake by 88% in Q2 2026, selling an estimated $2.64M and leaving 71,345 shares worth $560K. The position accounts for ﹤0.01% of the portfolio, ranked #754.

Voloridge Investment Management first reported a position in ABCL in Q2 2021 and has held it in 10 quarters since. The position peaked at $3.84M in Q2 2021. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Voloridge Investment Management held 71,345 shares of AbCellera Biologics worth $560K as of Q2 2026.
Voloridge Investment Management sold 539,078 AbCellera Biologics shares in Q2 2026, an estimated $2.64M.
AbCellera Biologics made up ﹤0.01% of Voloridge Investment Management's portfolio in Q2 2026, its #754 holding.
Voloridge Investment Management first reported a position in AbCellera Biologics in Q2 2021 and has held it in 10 quarters since.
Voloridge Investment Management's AbCellera Biologics position peaked at $3.84M in Q2 2021.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Voloridge Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.